Before founding and helming Ultima Genomics as CEO, Gilad Almogy, PhD, was the founder, president and CEO at Fulfil Solutions. He also founded and served as CEO of Cogenra, a startup company funded by Khosla Ventures that targeted the development and rapid proliferation of economically-viable solar power.
Previously, Gilad served as a senior VP at Applied Materials (AMAT) where he was an executive staff member leading the Display and Thin FilmSolar Products Business Group.
Gilad joined Applied through the acquisition of Orbot Instruments Ltd. Through a succession of R&D roles, he became General Manager of Applied Materials Israel in 2001, a role he held through 2007 while leading the organization to multiple new product introductions, significantly outgrowing the semiconductor equipment industry.
Gilad holds a BsC in Mathematics and Physics from the Hebrew University in Jerusalem and a PhD in Applied Physics from Caltech.
Gilad was recognized as ‘Hi-Tech Manager of the Year’ by the Israeli Institute of Management.
For the past five years, a startup backed by some of the biggest names in venture capital has been secretly developing a way to sequence genes faster, cheaper and at a bigger scale.
When talking about genomics biotechs, financing rounds tend to be more on the modest side — an $18.5 million Series A round for one, $21 million venture equity financing raise for another, and $98 million for Alice Zhang's Verge Genomics Series B from late last year. But all of those
With nearly half a dozen new short-read sequencing instruments slated for release in the US over the next year or two, it appears that competition is on its way.